Pathology Doctors in Ocala, FL Accepting Medicare

9 Pathology doctors found. Showing 1 - 9

Alan V Richman, MD Pathology - Forensic Pathology Medicare: Not Enrolled in Medicare Practice Location: 1500 Sw 1st Ave, Dept Of Pathology, Ocala, FL 34474 Phone: 352-351-7200

Miss Rachel Suzanne Redman, M.D. Pathology - Anatomic Pathology & Clinical Pathology Medicare: Not Enrolled in Medicare Practice Location: 1500 Sw 1st Ave, Munroe Regional Medical Center, Ocala, FL 34474 Phone: 352-351-7262

Manuel A Leal, MD Pathology - Forensic Pathology Medicare: Not Enrolled in Medicare Practice Location: 1500 Sw 1st Ave, Dept Of Pathology, Ocala, FL 34474 Phone: 352-351-7200

Philippine Brooke, MD Pathology - Cytopathology Medicare: Accepting Medicare Assignments Practice Location: 2850 Se Third Court, Ocala, FL 34471 Phone: 352-732-6474    Fax: 352-732-7205

William Robert Anderson, MD Pathology - Anatomic Pathology Medicare: Accepting Medicare Assignments Practice Location: 1160 Se 18th Pl, Ocala, FL 34471 Phone: 407-256-2171

Dr. Rudrama Pagidipati, Pathology - Clinical Pathology/Laboratory Medicine Medicare: Not Enrolled in Medicare Practice Location: 2955 Se 3rd Ct, Ocala, FL 34471 Phone: 352-622-7000    Fax: 352-622-7057

Dr. Jeffrey Eisenstein, M.D. Pathology - Anatomic Pathology & Clinical Pathology Medicare: Accepting Medicare Assignments Practice Location: 1431 Sw 1st Ave Dept Of, Ocala, FL 34471 Phone: 352-401-1539

Dr. Ioan Corneliu Cucoranu, M.D. Pathology - Clinical Pathology/Laboratory Medicine Medicare: Medicare Enrolled Practice Location: 3320 Sw 33rd Rd Ste 100, Ocala, FL 34474 Phone: 352-260-4700

David J Gray, DO Pathology - Anatomic Pathology & Clinical Pathology Medicare: Accepting Medicare Assignments Practice Location: 1431 Sw 1st Ave, Ocala, FL 34471 Phone: 352-401-1134    Fax: 352-732-0795

News Archive

Servier, Cortex sign new option agreement for AMPAKINE technology

Cortex Pharmaceuticals, Inc. entered into a new agreement with Servier to sell its remaining rights to the jointly discovered high impact AMPAKINE compound, CX1632.

FDA agrees to Oncogenex' proposed amendment to Phase 3 AFFINITY protocol

OncoGenex Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) has agreed to the Company's proposed amendment to the Phase 3 AFFINITY protocol and statistical analysis plan.

Celtic, Resolvyx enter option agreement for RX-10045 to treat dry eye syndrome

Celtic Therapeutics Holdings L.P. a successor firm to Celtic Pharma, and Resolvyx Pharmaceuticals, Inc. (Resolvyx) announced today that they have entered into an option agreement relating to Resolvyx's RX-10045, a late-stage program for the treatment of dry eye syndrome and other ophthalmic conditions.

Combining medicine switch with cognitive behavioral therapy can reduce symptoms of depression: Study

More than one-third of teenagers with treatment-resistant depression - many of whom had been depressed for more than two years - became symptom-free six months after switching their medication or combining a medicine switch with cognitive behavioral therapy during a multicenter study led by UT Southwestern Medical Center researchers.

Read more Medical News

› Verified 7 days ago